Nebraska Cannabis Legislation

LB933 grants healthcare practitioners immunity from prosecution under the Nebraska Medical Cannabis Patient Protection Act, protecting providers who recommend cannabis to patients.

LB316 restricts hemp products to CBD only, impacting consumer access, industry innovation, and public understanding of cannabis in Nebraska.

LB1235 amends Nebraska's Liquor Control Act and Medical Cannabis Regulation Act, impacting how cannabis is regulated and distributed, which affects patient access and the legal framework for operators.

LB877 adds specific substances to Nebraska's controlled substances list, impacting future cannabis-related product development and access for consumers and patients.

LB795 designates bromazolam as a controlled substance, corrects spelling of others, and enhances penalties for fentanyl offenses in Nebraska, impacting public safety and drug enforcement.

LB230 regulates kratom sales, restricts nitrous oxide access, and amends Nebraska's controlled substances act, impacting consumers and public health.

LB530 increases penalties for controlled substance violations, impacting consumers and the public through stricter enforcement.

LB1 corrects a clerical error in Nebraska's voter-approved medical cannabis initiative, ensuring the law accurately reflects the original intent for patients.

LB72 reschedules certain controlled substances in Nebraska, impacting patient access to specific medications and potentially future cannabis-related policy discussions.

LB475 classified tianeptine as a controlled substance, impacting consumer access and public health in Nebraska.

LB6 adds penalty enhancements for controlled substance violations causing serious injury or death, impacting public safety and the legal consequences for drug-related harm.